0HB0.L

Agios Pharmaceuticals, Inc. [0HB0.L] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

0HB0.L Stock Summary

Top 10 Correlated ETFs

0HB0.L

Top 10 Correlated Stocks

0HB0.L

In the News

0HB0.L Financial details

Company Rating
-
Market Cap
1.66B
Income
-352.09M
Revenue
26.82M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
383
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-6.02
Forward P/E
-
PEG
-1.21
P/S
55.08
P/B
1.49
P/C
-
P/FCF
-4.55
Quick Ratio
11.1
Current Ratio
12.06
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-6.34
EPS next Y
-
EPS next Q
-
EPS this Y
49.65%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-1.6%
Revenue last 5Y
-25.63%
Revenue Q/Q
-4%
EPS Q/Q
4.88%
-
-
-
-
SMA20
-5.88%
SMA50
-8.57%
SMA100
14.29%
Inst Own
-
Inst Trans
-
ROA
-22%
ROE
-22%
ROC
-0.41%
Gross Margin
-1687%
Oper. Margin
-1600%
Profit Margin
-914%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
20.13-35.3493
52W High
-13.54%
52W Low
+51.3%
RSI
36
Rel Volume
-
Avg Volume
522
Volume
1
Perf Week
-5.23%
Perf Month
-10.05%
Perf Quarter
12.83%
Perf Half Y
5.25%
-
-
-
-
Beta
0.855
-
-
Volatility
0.55%, 1.08%
Prev Close
-3.69%
Price
30.26
Change
-3.94%

Something similar

Top by Market Cap
MSF.DE
MSFT
0YXG.L
VTI
EMBASSY.NS
Top Correlated ETFs
CNAA.L
Top Correlated Stocks
CIZN
GLENMARK.NS
HIRECT.NS
NH.NS
REPCOHOME.NS
Similar Market Cap
GLPG
ECVT
600365.SS
ELMD3.SA
LABU

Company Profile

Healthcare Medical - Pharmaceuticals
  • Volume Average 522
  • Market Capitalization 1.66B
  • Employee 383
  • CEO Mr. Brian M. Goff M.B.A.
  • Headquarters Cambridge,MA,US
  • IPO Date 2018-01-29
  • Website https://www.agios.com

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.